Please assess the completion status of the following clinical trial:

Trial Title: Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability and willingness to give informed consent~* Age ≥ 18 years~* HIV-1 infection documented at any time prior to study entry~* Fasting plasma triglyceride value between 200 and 1000 mg/dL on two occasions within 4 weeks~* Subjects must be receiving a stable antiretroviral medication regimen for \> 3 months without any anticipated changes during the study interval~* Females must not be pregnant or lactating. Females of childbearing potential and males must use a reliable means of contraception~* On stable lipid modification pharmacotherapy for at least 8 weeks prior to study entry~Exclusion Criteria~* Hemoglobin A1C \> 8.5 %~* Uncontrolled hypothyroidism (TSH \> 4.5)~* HIV viral load \> 5,000 copies/ml (cpm),~* Active liver disease and/or liver transaminases greater than 2.0 X upper limit of normal~* Active kidney disease or serum creatinine \> 2.5 mg/dL~* Myocardial infarction, unstable ischemic heart disease, stroke, or coronary revascularization procedure~* Uncontrolled hypertension within 4 weeks of study entry (SBP \> 180 mmHg or DBP \> 100 mmHg)~* Use of systemic cancer chemotherapy within 8 weeks of study entry~* Pregnancy or breastfeeding~* Drug or alcohol dependence, or other conditions which may affect study compliance~* History of coagulopathy or use of anticoagulants such as warfarin~* Use of omega-3 fatty acid preparation in the 12 weeks prior to randomization~* Significant changes in clinical status from the Screening Visit which would preclude the patient from being an appropriate candidate.~* Any of the following laboratory parameters: hematocrit \< 25%, absolute neutrophil count \< 1.5 x 10\^9/L, platelets \< 100 x 10\^9/L or hemoglobin \< 8.0 gm/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LOVAZA (Type: EXPERIMENTAL): 4 g/d of omega-3 fatty acid esters, plus dietary counseling
- Placebo (Type: PLACEBO_COMPARATOR): Corn oil placebo, plus dietary counselling

Based on this trial design, predict the completion outcome and termination type (if applicable).